Catalog No.
DHJ38901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
IL17R, CDw217, IL-17RA, Interleukin-17 receptor A, IL-17 receptor A, IL17RA, CD217
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q96F46
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AMG827, KHK4827, CAS: 1174395-19-7
Clone ID
Brodalumab
Brodalumab, PMID: 29261896
The safety of brodalumab for the treatment of psoriasis, PMID: 32053396
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis, PMID: 26422722
Brodalumab: A Review of Safety, PMID: 29562088
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials, PMID: 33106286
Brodalumab: A Review in Moderate to Severe Plaque Psoriasis, PMID: 29516365
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials, PMID: 31583255
Brodalumab, PMID: 31643345
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review, PMID: 32427307
Brodalumab for the treatment of plaque psoriasis: up-to-date, PMID: 30831036
[Brodalumab], PMID: 31204123
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis, PMID: 29532693
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial, PMID: 31175909
Brodalumab, PMID: 29999957
Brodalumab in the treatment of chronic plaque psoriasis, PMID: 32463723
Brodalumab in psoriasis: evidence to date and clinical potential, PMID: 31024633
Brodalumab: A new way to inhibit IL-17 in psoriasis, PMID: 32285564
Brodalumab for the treatment of psoriasis, PMID: 27718760
The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities, PMID: 33488920
Recapture Rate of Brodalumab in Patients With a Lapse in Treatment, PMID: 32272515
Two-Year US Pharmacovigilance Report on Brodalumab, PMID: 33337520
Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal, PMID: 30112635
One-Year Pharmacovigilance Update of Brodalumab, PMID: 32845586
Malignancy Rates in Brodalumab Clinical Studies for Psoriasis, PMID: 32207067
Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials, PMID: 27221323
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis, PMID: 26914406
Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics, PMID: 32533554
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics, PMID: 30772098
Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review, PMID: 31939925
Brodalumab: the first anti-IL-17 receptor agent for psoriasis, PMID: 28650001
Brodalumab in the treatment of recalcitrant acrodermatitis continua of Hallopeau, PMID: 32920959
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis, PMID: 29323542
Brodalumab: another helpful option for HIV-positive psoriatic patients?, PMID: 32584458
Brodalumab: short-term effectiveness and safety in real clinical practice, PMID: 32227476
Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis, PMID: 28197901
Paradoxical gastrointestinal effects of interleukin-17 blockers, PMID: 32719044
Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials, PMID: 32250714
Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents, PMID: 30017705
Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy, PMID: 28744098
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis, PMID: 28460549
Brodalumab treatment in psoriasis patients with severe renal failure, PMID: 33228335
New Treatment Addressing the Pathogenesis of Psoriasis, PMID: 33050592
Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study, PMID: 32275086
Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis, PMID: 25985813
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience, PMID: 32916767
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis, PMID: 32022825
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis, PMID: 30181299
Psoriasis pathogenesis and the development of novel targeted immune therapies, PMID: 28887948
Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1), PMID: 32286683
Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors, PMID: 33221464
For research use only. Not for human or drug use.
